Phathom Pharmaceuticals, Inc.
- PHAT
- NASDAQ
- Biotechnology
- Gastrointestinal (GI) Drugs
- Acid Blocker (P-CAB)
- Clinical-Stage Biopharma
$6.92
Today −7.73%Quote Oct 16, 2026, 08:00 PM UTC
−10.71%over the last month
Max drawdown −13.7%From 1-month high −10.8%3 months −35.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$559.8M
Quote Oct 16
Next earnings
Oct 29
Expected, not confirmed
Analyst target
$17.33
+150.4% from here
Floor
$6.75
2.5% below price
Where the price sits
9 analysts
Analyst range, low to high
$10.00$22.00
- Price $6.92
- Resistance $6.92–$6.98
- Consensus $17.33
Analysts' average target sits about 150% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PHATPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
371